MorphoSys Presents New Long-Term Data from L-MIND Suggesting

The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth Annual Meet

Related Keywords

Germany , United States , United Kingdom , Texas , Planegg , Bayern , Massachusetts , Boston , Houston , Canada , Johannes Duell , Development Officer , Linkedin , Xencor Inc , Twitter , Drug Administration , Morphosys Us Inc , Meeting Of The Society Hematologic Oncology , University Hospital Wuerzburg Medical Clinic , Tenth Annual Meeting , Hematologic Oncology , Malte Peters , Morphosys Chief Research , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety ,